全文获取类型
收费全文 | 263篇 |
免费 | 17篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 3篇 |
妇产科学 | 2篇 |
基础医学 | 28篇 |
口腔科学 | 10篇 |
临床医学 | 24篇 |
内科学 | 61篇 |
皮肤病学 | 3篇 |
神经病学 | 14篇 |
特种医学 | 4篇 |
外科学 | 94篇 |
综合类 | 2篇 |
预防医学 | 14篇 |
眼科学 | 2篇 |
药学 | 16篇 |
肿瘤学 | 2篇 |
出版年
2022年 | 3篇 |
2021年 | 12篇 |
2020年 | 4篇 |
2019年 | 6篇 |
2018年 | 5篇 |
2017年 | 6篇 |
2016年 | 5篇 |
2015年 | 5篇 |
2014年 | 12篇 |
2013年 | 9篇 |
2012年 | 19篇 |
2011年 | 15篇 |
2010年 | 11篇 |
2009年 | 9篇 |
2008年 | 16篇 |
2007年 | 17篇 |
2006年 | 8篇 |
2005年 | 19篇 |
2004年 | 6篇 |
2003年 | 6篇 |
2002年 | 9篇 |
2001年 | 12篇 |
2000年 | 11篇 |
1999年 | 3篇 |
1998年 | 1篇 |
1995年 | 1篇 |
1992年 | 3篇 |
1991年 | 3篇 |
1990年 | 7篇 |
1989年 | 4篇 |
1988年 | 3篇 |
1987年 | 6篇 |
1985年 | 2篇 |
1984年 | 6篇 |
1983年 | 3篇 |
1982年 | 1篇 |
1981年 | 1篇 |
1978年 | 3篇 |
1977年 | 3篇 |
1976年 | 6篇 |
1974年 | 2篇 |
1973年 | 1篇 |
1959年 | 1篇 |
排序方式: 共有285条查询结果,搜索用时 15 毫秒
1.
Antimurine antibody formation following OKT3 therapy 总被引:1,自引:0,他引:1
T J Schroeder M R First M E Mansour P E Hurtubise S Hariharan F C Ryckman R Munda D B Melvin I Penn W F Ballistreri 《Transplantation》1990,49(1):48-51
OKT3 is an IgG2a murine monoclonal antibody directed against the CD3 antigen receptor of human T lymphocytes. A major concern with OKT3 treatment in solid organ transplant recipients is the development of antimouse antibody, which may preclude retreatment with this agent. We have administered OKT3 on 215 occasions (150 renal, 34 hepatic, 26 cardiac, 5 pancreatic) in 179 patients between April 1982 and December 1988. The mean duration of treatment was 10.5 days (range, 2-22 days). Antimouse antibody data were analyzed on the most recent 133 treatment courses where the antibody status was available pretreatment. Determination of antimouse antibody production was elicited by ELISA technology at days 0, 7, 14, and 28 of OKT3 treatment. Patients were categorized according to the antibody response as follows: (a) absence of antibody; (b) low titer (1:100); or (c) high titer (greater than or equal to 1:1000). Our earlier experience has demonstrated that retreatment with OKT3 is successful in groups a and b. The development of antimurine antibodies was analyzed with regard to the following parameters: (1) The duration of OKT3 treatment; (2) treatment type (prophylactic, primary, or secondary); (3) primary treatment or retreatment; (4) concomitant immunosuppressive regimen (double or triple therapy); (5) dosage of concomitant immunosuppressive drugs; and (6) transplant organ type. The following results were obtained. (1) Duration of treatment had no effect on antibody production (11.0 days in antibody negative and 10.0 days in antibody positive). (2) There was no difference in antibody formation rates for the first treatment of OKT3 when it was used as prophylaxis (26%), primary (19%), or secondary (27%) therapy. (3) Antibody formation rate with first treatment was 29%; with retreatment, patients who were antibody negative following first treatment became positive in 28% of cases, and retreated patients who were low titer positive following first treatment converted to high titer in 57% of cases. (4) Antibody formation was higher in patients receiving double immunosuppressive therapy (36%) than in those receiving triple immunosuppressive therapy (21%) during OKT3 treatment. (5) Concomitant immunosuppression was lower in the antibody-positive group during OKT3 therapy: steroids, 61 mg/day vs. 52 mg/day; azathioprine, 89 mg/day vs. 66 mg/day; CsA, 317 mg/day vs. 186 mg/day. (6) Antibody formation rates were lower in non-renal transplants following first treatment with OKT3 (liver 17%, heart 17%, kidney 28%); this reflects the higher doses of concomitant immunosuppressive therapy used in nonrenal transplants.(ABSTRACT TRUNCATED AT 400 WORDS) 相似文献
2.
3.
Matic G Hofmann D Winkler R Tiess M Michelsen A Schneidewind JM Hebestreit G Keysser M Müller W Kinze EM Ramlow W 《Artificial organs》2000,24(2):103-107
Elimination of IgG can be achieved by extracorporeal immunoadsorption (IA) based on specific binding to either staphylococcal protein A (Excorim) or sheep polyclonal antibodies directed against human IgG (Therasorb). In 602 analyzed sessions of IA, elimination of IgG was 60% through 80% depending on the treated plasma volume, with no significant difference between the mentioned systems. However, the decrease of IgM and IgA was approximately 50% in the anti-IgG compared to 20-40% in the protein A system. Plasma albumin concentration decreased by 20% in the anti-IgG system compared to 15% in the protein A system, and hemoglobin values increased by 2% in the anti-IgG system and decreased by 6% in the protein A system. In conclusion, a clinical relevance for these findings cannot be ruled out, and the individual choice might depend on the clinical situation and laboratory findings. 相似文献
4.
Martins K Ahrenholz P Matic GB Hofmann D Tiess M Winkler RE Ramlow W 《Artificial organs》2000,24(7):526-532
Release of microparticles into the blood during extracorporeal circulation must be kept low because of possibly serious acute and chronic adverse effects. Concentration and size distribution of microparticles were measured during simulated treatments (n = 7) on original equipment for 2 standard low-density lipoprotein (LDL) elimination procedures (DALI 750, Fresenius AG, St. Wendel, Germany and Liposorber, Kaneka Corporation, Osaka, Japan) and compared to hemofiltration solutions. For both systems as well as in hemofiltration solutions, the mean particle concentrations in 500 ml portions gathered from the efferent blood line stayed below 10% of pharmacopoeia standards for infusion solutions (United States Pharmacopoeia, European Pharmacopoeia) in all measured size classes. Although particle concentrations were comparable in all systems, the mean total number of particles > or =2 microm released per session was lowest in the DALI (167,000) compared to the Liposorber (465,000) and hemofiltration solutions (2,240,000). This was mainly due to different total processed blood volumes necessary to achieve the required LDL reduction. 相似文献
5.
6.
7.
Ana Martins Figueiredo Pedro Barbacena Ana Russo Silvia Vaccaro Daniela Ramalho Andreia Pena Aida Pires Lima Rita Rua Ferreira Marta Alves Fidalgo Fatima El-Marjou Yulia Carvalho Francisca Ferreira Vasconcelos Ana-Maria Lennon-Dumnil Danijela Matic Vignjevic Claudio Areias Franco 《Proceedings of the National Academy of Sciences of the United States of America》2021,118(18)
8.
9.
Antonija Jurela Dario Repic Slavica Pejda Hrvoje Juric Renata Vidakovic Igor Matic Andrija Bosnjak 《The Angle orthodontist》2013,83(1):140
Objective:To determine the difference in the levels of Streptococcus mutans and S sobrinus in stimulated saliva in orthodontic patients with different bracket types (stainless steel and esthetic brackets) using polymerase chain reaction and cultivation method.Materials and Methods:Thirty-two patients, aged 13 to 30 years, were selected following these criteria: 1) orthodontic treatment indication, 2) systemic health, and 3) no tobacco and antibiotic consummation for three months prior to the commencement of the study. Patients were divided into two groups according to the bracket type; 16 patients formed the conventional bracket group (stainless steel brackets), and 16 patients formed the esthetic bracket group (plastic brackets). The levels of S mutans and S sobrinus in stimulated whole saliva samples were collected prior to fixed orthodontic appliance placement (T1) and 12 weeks after placement (T2), as were the Decayed, Missing, and Filled Surface Index (DMFS) and Oral Hygiene Index-Simplified (OHI-S). Mann-Whitney, Wilcoxon, and chi-square tests were used for statistical analysis.Results:Statistical analysis (chi-square test) showed no difference in S mutans and S sobrinus counts among patients with different brackets at either T1 or T2. There was no difference in total bacteria counts after fixed orthodontic appliance placement.Conclusion:The number of colony-forming units of S mutans and S sobrinus in stimulated saliva samples does not seem to be significantly different between patients with stainless steel brackets and patients with plastic brackets. 相似文献
10.